Deals and Financings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Only a month after buying the tissue regeneration company Derma Sciences, Integra has announced a much larger acquisition for Codman Neurosurgery. The company says the buy would complement its current neurosurgery portfolio and boost its global reach.
Latest From Deals
On this week's Medtech Insight podcast: US House Ways and Means Committee sets out plans for the next two years, including a review of all taxes and fees connected to the Affordable Care Act; Allergan and Hologic enter into separate big-money acquisitions in the aesthetics devices arena; a deep-dive look at the osteoporosis diagnostics market.
An Israeli start-up developing an injectable, miniature continuous blood glucose monitoring implant has secured funding from the Juvenile Diabetes Research Foundation (JDRF) to speed up product development. The investment will be used to bring GluSense closer to its first in-human clinical trial.
Hologic is acquiring Cynosure for $1.65bn, saying medical aesthetics will complement its existing OB/GYN and women’s health businesses. It is the latest in a series of recent moves intended to accelerate Hologic’s growth.
Transcatheter aortic valve replacement specialist Symetis has made its maiden acquisition, buying preclinical-stage mitral valve repair firm Middle Peak Medical.
Zeltiq's CoolSculpting body-contouring system will be the third "pillar" in Allergan's aesthetics business, along with its existing facial aesthetics and plastic and regenerative surgery lines, the company says.
Divesting an underperforming and/or non-core asset could help reinvigorate a medtech business. But what are the issues that arise for the sellers of those assets, as well as the buyers, during the carve-out process? Jane Hobson and Phelim O'Doherty of Baker McKenzie discuss what the common issues are and how to address them in this guest column.
The $1bn in cash and stock deal will create a pure-play infusion therapy company with estimated revenue of about $1.45bn.
2017 has not got off to a bullish start, with January’s total venture financing deal value barely making it half way past last year’s level. The biggest round, at $40m, went to preterm birth risk specialist Sera Prognostics, catching the eye of the largest lab services provider in the US, LabCorp.
2017 kicked off with 12 medtech M&A acquisitions in January, a decline from the 18 M&A deals recorded in the same month last year, and two fewer than the previous month.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.